Журнал кардиореспираторных исследований 2025. №2/2

Maqola mavzusi

MIELOMA KASALLIGIDA GRANULOTSITIK KOLONIYANI STIMULLOVCHI OMIL YORDAMIDA AUTOLOGIK GEMATOPOETIK O‘ZAK HUJAYRALARI TRANSPLANTATSIYASI VA TRANSPLANTATSIYADAN KEYINGI DAVR (11-16)

Mualliflar

Amerova Dilafruz Abdixalimovna, Maxmonov Lutfulla Saydullayevich, Mamatkulova Feruza Xaydarovna, Muyiddinov Zuxriddin Ziyadullayevich Temirov Nuriddin Najmiddinovich, Shomurodov Qodir Ergashovich,

Muassasa

Samarqand Davlat Tibbiyot universiteti, Samarqand viloyat ko‘p tarmoqli tibbiyot markazi

Annotatsiya

Autologik gematopoetik o’zak hujayralarini transplantatsiyasi (auto-GIНT), proteaza ingibitorlari va yangi immunomodulyatorlarni o‘z ichiga olgan yangi dorilarni qo‘llanilyotganiga qaramay, inson hujayralari shuningdek, monoklonal antitanalar, somatik holatiga ko‘ra, yuqori dozali davolanish uchun potensial nomzodlar deb hisoblangan ko‘p sonli miyeloma bilan (MM) bemorlarni davolash algoritmida asosiy o‘rinni saqlab qoladi [1-3]. AutoGIXT bir necha bosqichda ketma-ket amalga oshirishni o‘z ichiga oladi, bunda transplantatsiyadan oldingi va keyingi davrlarda ishlatiladigan koloniyani stimullovchi granulotsitlar (K-CG) muhim o‘rinni egallaydi. Shunday qilib, suyak iligidan ildiz hujayralarini periferik qonga safarbar qilish uchun o‘sish omilidan foydalanish autotransplantantni muvaffaqiyatli tayyorlash uchun zarur shartdir. Bunday holda, o‘sish omili alohida yoki sitostatiklar va/yoki pleriksafor bilan birgalikda ishlatilishi mumkin [4]. Bir tomondan, o‘sish omili gematopoezni tez tiklash, yuqumli asoratlarni kamaytirish va kasalxonaga yotqizish muddatini qisqartirish sharti sifatida qaralsa, [5-8]. boshqa tomondan, bir qator mualliflar ushbu ko‘rsatkichlarda sezilarli o‘zgarishlarni aniqlay olmadilar, bu G-SG dan rejalashtirilgan foydalanishni rad etish uchun asos sifatida qaraladi [9, 10]. Bundan tashqari, yo‘ldosh terapiyaning o‘sish omilidan qochish o‘sish sindromining rivojlanishiga to‘sqinlik qilishi mumkin.

Kalit so'zlar

ko‘p sonli miyelomа, ауtologik gematomapoetik o’zak hujayralari transplantatsiyasi, granulotsitlar kolonistimulyatsiya qiluvchi omil, Pegfio’lgrastim.

Adabiyotlar

1. Bessmeltsev SS, Abdulkadyrov KM. Mnozhestvennaya mieloma: rukovodstvo dlya vrachei. (Multiple myeloma: manual for physicians.) Moscow: SIMK Publ.; 2016. 512 p. (In Russ)] 2. [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl 2):1–24. doi: 10.18821/0234-5730-2016-61-1-S2-1-24. (In Russ)] 3. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–20. doi: 10.1056/NEJMoa1611750. 4. [Gritsaev SV, Kuzyaeva AA, Bessmel’tsev SS. Certain Aspects of Autologous Hematopoietic Stem Ce ll Transplantation in Patients with Multiple Myeloma. Clinical oncohematology. 2017;10(1):7–12. doi: 10.21320/2500-2139-2017-10-1-7-12. (In Russ)] 5. Trivedi M, Martinez S, Corringham S, et al. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009;43(12):895–908. doi: 10.1038/bmt.2015.75. 6. Cox JE, Campos S, Wu J, et al. Effi cacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014;49(2):219–22. doi: 10.1038/bmt.2013.149. 7. Sborov DW, Cho YK, Cottini F, et al. G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leuk Lymphoma. 2017;58(12):2947–51. doi: 10.1080/10428194.2017.1318436. 8. Samaras P, Blickenstorfer M, Siciliano RD, et al. Pegfi lgrastim reduces the length of hospitalization and the time to eng raftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with fi lgrastim. Ann Hematol. 2011;90(1):89–94. doi: 10.1007/s00277-010-1036-8. 9. Gertz MA, Gastineau DA, Lacy MQ, et al. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant. 2016;46(7):956–61. doi: 10.1038/bmt.233. 10. Martinez-Cibrian N, Magnano L, Gutierrez-Garcia G, et al. At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study. Bone Marrow Transplant. 2016;51(4):593–5. doi: 10.1038/bmt.2015.287. 11. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant.;27(9):893– 8. doi: 10.1038/ sj.bmt.1703015. 12. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J. 2018;8(12):123. doi: 10.1038/s41408-018-0155-7. 13. Hari P, Reece DE, Randhawa J, et al. Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019;54(2):293–9. doi: 10.1038/s41409-018-0261-y. 14.Gritsaev SV, Kostroma II, Zhernyakova AA, et al. Experience with the Use of Thio/Mel Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clinical oncohematology. 2019;12(3):282–8. doi: 10.21320/2500-2139-2019-12-3-282-288. (In Russ)] 15. Sato S, Tamai Y, Okada S, et al. Atraumatic splenic rupture due to ectopic extramedullary hematopoiesis after autologous stem cell transplantation in a patient with AL amyloidosis. Intern Med. 2018;57(3):399–402. doi: 10.2169/internalmedicine.9018- 17. 16. Chen J, Pan J, Zhan T, et al. Autologous stem cell transplantation for multiple myeloma: growth factor matters. Biol Blood Marrow Transplant. 2019;25(9):e293– e 297. doi: 10.1016/j.bbmt.2019.05.035. 17. Gutierrez-Garcia G, Rovira M, Magnano L, et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53(12):1541–7. doi: 10.1038/s41409-018-0189-2. 18. Cho YK, Irby DJ, Li J, et al. Pharmacokinetic-pharmacodynamic model of neutropenia in patients with myeloma receiving high-dose melphalan for autologous stem cell transplant. CPT: Pharmacometr Syst Pharmacol. 2018;7(11):748–58. doi: 10.1002/psp4.12345. 19. Kostroma II, Zhernyakova AA, Chubukina ZhV, et al. Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Infl uence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT. Clinical oncohematology. 2018;11(2):192–7. doi: 10.21320/2500-2139-2018-11-2-192-197. (In Russ)] 20. Kostroma II, Zhernyakova AA, Gritsaev SV. Some aspects of autotransplant collection in patients with multiple myeloma. Voprosy onkologii. 2019;65(4):504–9. (In Russ)] 21. Khusinova, S. A., Khakimova, L. R., Ablakulova, M. K., & Yuldashova, N. E. (2021). Assessment of the Information of Polyclinic Doctors about the Principles of Rational Purposing of Medicines. Annals of the Romanian Society for Cell Biology, 25(1), 6576-6581.